← Leaderboards
Priya Uppuluri
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$2,863,939
Attributed
$2,863,939
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $614K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,863,939 · 4
By mechanism
R01$1,508,625 · 1
R21$1,355,314 · 3
Top collaborators
No co-investigators on record.
Most similar at Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
Same institution · by research overlap
- Ashraf S. Ibrahim$17,102,127
- Scott G Filler$18,258,232
- Shakti Singh$269,800
- Tim Cooke$590,649
Others in their field
Other Emerging Leaders on “Disseminated Candidiasis”
- Terry Roemer · Prokaryotics, Inc.$1,732,733
- Anna Huppler · Medical College Of Wisconsin$860,136
- Tim Cooke · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center$590,649
- Anna M. Selmecki · University Of Minnesota$491,174
- Abhiram Maddi · State University Of New York At Buffalo$241,051
- Charles Joel McManus · Carnegie-Mellon University$234,425
Research focus
Disseminated CandidiasisCellsCandida AlbicansProteinsInvadedIn VitroCandidiasisCandidaMedical DeviceMycosesVirulenceInfectionTraitYeastsPharmaceutical PreparationsGenesPreventMicrobial BiofilmsFda ApprovedMouse ModelGrowthIn VivoAntifungal AgentsCatheters
Grant awards (10)
Delineating host response to central venous catheter associated Candida albicans biofilm infections, and development of novel therapeutics to combat drug resistant biofilms$198,554
R21 · FY2025 · AI · contact PI
Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs$256,025
R21 · FY2024 · AI · contact PI
Delineating host response to central venous catheter associated Candida albicans biofilm infections, and development of novel therapeutics to combat drug resistant biofilms$253,085
R21 · FY2024 · AI · contact PI
Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs$201,875
R21 · FY2023 · AI · contact PI
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis$353,129
R01 · FY2022 · AI · contact PI
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis$393,191
R01 · FY2021 · AI · contact PI
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis$391,471
R01 · FY2020 · AI · contact PI
Development of Immunotherapeutic Strategies to Overcome Neonatal Candidiasis$202,625
R21 · FY2020 · HD · contact PI
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis$370,834
R01 · FY2019 · AI · contact PI
Development of Immunotherapeutic Strategies to Overcome Neonatal Candidiasis$243,150
R21 · FY2019 · HD · contact PI